Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Defining Value for Pancreatic Surgery in Early-Stage Pancreatic Cancer.

Bateni SB, Gingrich AA, Hoch JS, Canter RJ, Bold RJ.

JAMA Surg. 2019 Aug 21:e193019. doi: 10.1001/jamasurg.2019.3019. [Epub ahead of print]

PMID:
31433465
2.

Hospital Utilization Among Rural Children Served by Pediatric Neurology Telemedicine Clinics.

Dayal P, Chang CH, Benko WS, Pollock BH, Crossen SS, Kissee J, Ulmer AM, Hoch JS, Warner L, Marcin JP.

JAMA Netw Open. 2019 Aug 2;2(8):e199364. doi: 10.1001/jamanetworkopen.2019.9364.

PMID:
31418803
3.

Re: Choosing the discount rate in an economic analysis.

Singh S, Cheek JA, Babl FE, Hoch JS.

Emerg Med Australas. 2019 Aug 4. doi: 10.1111/1742-6723.13369. [Epub ahead of print] No abstract available.

PMID:
31379134
4.

Review article: A primer for clinical researchers in the emergency department: Part X. Understanding economic evaluation alongside emergency medicine research.

Singh S, Cheek JA, Babl FE, Hoch JS.

Emerg Med Australas. 2019 Jun 24. doi: 10.1111/1742-6723.13320. [Epub ahead of print] Review.

PMID:
31237083
5.

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial.

Hoch JS, Hay A, Isaranuwatchai W, Thavorn K, Leighl NB, Tu D, Trenaman L, Dewa CS, O'Callaghan C, Pater J, Jonker D, Chen BE, Mittmann N.

BMC Cancer. 2019 Jun 7;19(1):552. doi: 10.1186/s12885-019-5779-x.

6.

Adherence to human epidermal growth factor receptor-2 testing and adjuvant trastuzumab treatment guidelines in Ontario.

Marshall DA, Ferrusi IL, Trudeau M, Leighl NB, Hoch JS, Grazziotin LR, Khong H, Pullenayegum E, Earle CC.

J Oncol Pharm Pract. 2019 Jun 2:1078155219850299. doi: 10.1177/1078155219850299. [Epub ahead of print]

PMID:
31156051
7.

Cost-effectiveness of docetaxel in high-volume hormone-sensitive metastatic prostate cancer.

Beca J, Majeed H, Chan KKW, Hotte SJ, Loblaw A, Hoch JS.

Can Urol Assoc J. 2019 Apr 26. doi: 10.5489/cuaj.5889. [Epub ahead of print]

PMID:
31039109
8.

Patient-level resource use for injury admissions in Canada: A multicentre retrospective cohort study.

Porgo TV, Moore L, Truchon C, Berthelot S, Stelfox HT, Cameron PA, Gabbe BJ, Hoch JS, Evans DC, Lauzier F, Bernard F, Turgeon AF, Clément J.

Injury. 2019 Jun;50(6):1192-1201. doi: 10.1016/j.injury.2019.03.038. Epub 2019 Mar 28.

PMID:
31000192
9.

Clinical Outcomes and Costs Following Unplanned Excisions of Soft Tissue Sarcomas in the Elderly.

Bateni SB, Gingrich AA, Jeon SY, Hoch JS, Thorpe SW, Kirane AR, Bold RJ, Canter RJ.

J Surg Res. 2019 Jul;239:125-135. doi: 10.1016/j.jss.2019.01.055. Epub 2019 Feb 27.

PMID:
30825757
10.

Estimating the clinical cost of drug development for orphan versus non-orphan drugs.

Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Orphanet J Rare Dis. 2019 Jan 10;14(1):12. doi: 10.1186/s13023-018-0990-4.

11.

The Effectiveness and Value of Patisiran and Inotersen for Hereditary Transthyretin Amyloidosis.

Mickle K, Lasser KE, Hoch JS, Cipriano LE, Dreitlein WB, Pearson SD.

J Manag Care Spec Pharm. 2019 Jan;25(1):10-15. doi: 10.18553/jmcp.2019.25.1.010. Review.

12.

Toward Effective Work Accommodations for Depression: Examining the Relationship Between Different Combinations of Depression Symptoms and Work Productivity Losses.

Dewa CS, Hoch JS, Nieuwenhuijsen K, Parikh SV, Sluiter JK.

J Occup Environ Med. 2019 Jan;61(1):75-80. doi: 10.1097/JOM.0000000000001486.

PMID:
30358657
13.

Drivers of Cost for Pancreatic Surgery: It's Not About Hospital Volume.

Bateni SB, Olson JL, Hoch JS, Canter RJ, Bold RJ.

Ann Surg Oncol. 2018 Dec;25(13):3804-3811. doi: 10.1245/s10434-018-6758-1. Epub 2018 Sep 14.

PMID:
30218244
14.

Xylitol for the prevention of acute otitis media episodes in children aged 2-4 years: protocol for a pragmatic randomised controlled trial.

Persaud N, Laupacis A, Azarpazhooh A, Birken C, Hoch JS, Isaranuwatchai W, Maguire JL, Mamdani MM, Thorpe K, Allen C, Mason D, Kowal C, Bazeghi F, Parkin P; TARGet Kids! Collaboration.

BMJ Open. 2018 Aug 5;8(8):e020941. doi: 10.1136/bmjopen-2017-020941.

15.

Economic evaluation of smoking cessation in Ontario's regional cancer programs.

Djalalov S, Masucci L, Isaranuwatchai W, Evans W, Peter A, Truscott R, Cameron E, Mittmann N, Rabeneck L, Chan K, Hoch JS.

Cancer Med. 2018 Sep;7(9):4765-4772. doi: 10.1002/cam4.1495. Epub 2018 Jul 17.

16.

The effectiveness of 6 versus 12-months of dialectical behaviour therapy for borderline personality disorder: the feasibility of a shorter treatment and evaluating responses (FASTER) trial protocol.

McMain SF, Chapman AL, Kuo JR, Guimond T, Streiner DL, Dixon-Gordon KL, Isaranuwatchai W, Hoch JS.

BMC Psychiatry. 2018 Jul 17;18(1):230. doi: 10.1186/s12888-018-1802-z.

17.

Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom.

Whitehurst DGT, Latimer NR, Kagan A, Palmer R, Simmons-Mackie N, Victor JC, Hoch JS.

Pharmacoecon Open. 2018 Sep;2(3):225-231. doi: 10.1007/s41669-018-0083-2.

18.

A Comparison of Healthcare Use and Costs for Workers with Psychiatric Disabilities Employed in Social Enterprises Versus Those Who Are Not Employed and Seeking Work.

Dewa CS, Hoch JS, Corbière M, Villotti P, Trojanowski L, Sultan-Taïeb H, Zaniboni S, Fraccaroli F.

Community Ment Health J. 2019 Feb;55(2):202-210. doi: 10.1007/s10597-018-0281-5. Epub 2018 May 8.

PMID:
29737444
19.

The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS.

Pharmacoecon Open. 2018 Sep;2(3):255-270. doi: 10.1007/s41669-017-0051-2.

20.

Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).

Masucci L, Beca J, Sabharwal M, Hoch JS.

Pharmacoecon Open. 2017 Dec;1(4):255-263. doi: 10.1007/s41669-017-0018-3.

21.

Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology.

Jayasundara K, Krahn M, Mamdani M, Hoch JS, Grootendorst P.

Pharmacoecon Open. 2017 Sep;1(3):167-173. doi: 10.1007/s41669-017-0022-7.

22.

The economic burden of cancer care in Canada: a population-based cost study.

de Oliveira C, Weir S, Rangrej J, Krahn MD, Mittmann N, Hoch JS, Chan KKW, Peacock S.

CMAJ Open. 2018 Jan 4;6(1):E1-E10. doi: 10.9778/cmajo.20170144. Epub 2018 Jan 4.

23.

Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment.

Beca J, Husereau D, Chan KKW, Hawkins N, Hoch JS.

Pharmacoeconomics. 2018 Jan;36(1):7-15. doi: 10.1007/s40273-017-0583-4.

PMID:
29110141
24.

The clinical significance of occult gynecologic primary tumours in metastatic cancer.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS.

Curr Oncol. 2017 Oct;24(5):e368-e378. doi: 10.3747/co.24.3594. Epub 2017 Oct 25.

25.

Cost analysis of breast cancer diagnostic assessment programs.

Honein-AbouHaidar GN, Hoch JS, Dobrow MJ, Stuart-McEwan T, McCready DR, Gagliardi AR.

Curr Oncol. 2017 Oct;24(5):e354-e360. doi: 10.3747/co.24.3608. Epub 2017 Oct 25.

26.

Systematic review and network meta-analysis on the relative efficacy of osteoporotic medications: men with prostate cancer on continuous androgen-deprivation therapy to reduce risk of fragility fractures.

Poon Y, Pechlivanoglou P, Alibhai SMH, Naimark D, Hoch JS, Papadimitropoulos E, Hogan ME, Krahn M.

BJU Int. 2018 Jan;121(1):17-28. doi: 10.1111/bju.14015. Epub 2017 Oct 15. Review.

27.

COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008.

Ismail Z, Peacock SJ, Kovacic L, Hoch JS.

Int J Technol Assess Health Care. 2017 Jan;33(4):481-486. doi: 10.1017/S0266462317000642. Epub 2017 Sep 5.

PMID:
28871898
28.

Cost-effectiveness analysis of a multifactorial fall prevention intervention in older home care clients at risk for falling.

Isaranuwatchai W, Perdrizet J, Markle-Reid M, Hoch JS.

BMC Geriatr. 2017 Sep 1;17(1):199. doi: 10.1186/s12877-017-0599-9.

29.

Effect of High-Dose vs Standard-Dose Wintertime Vitamin D Supplementation on Viral Upper Respiratory Tract Infections in Young Healthy Children.

Aglipay M, Birken CS, Parkin PC, Loeb MB, Thorpe K, Chen Y, Laupacis A, Mamdani M, Macarthur C, Hoch JS, Mazzulli T, Maguire JL; TARGet Kids! Collaboration.

JAMA. 2017 Jul 18;318(3):245-254. doi: 10.1001/jama.2017.8708.

30.

Selected Use of Telemedicine in Intensive Care Units Based on Severity of Illness Improves Cost-Effectiveness.

Yoo BK, Kim M, Sasaki T, Hoch JS, Marcin JP.

Telemed J E Health. 2018 Jan;24(1):21-36. doi: 10.1089/tmj.2017.0069. Epub 2017 Jun 29.

PMID:
28661790
31.

Work-related experiences of head and neck cancer survivors: an exploratory and descriptive qualitative study.

Dewa CS, Trojanowski L, Tamminga SJ, Ringash J, McQuestion M, Hoch JS.

Disabil Rehabil. 2018 Jun;40(11):1252-1258. doi: 10.1080/09638288.2017.1291764. Epub 2017 Feb 25.

PMID:
28637151
32.

A cluster-randomized trial to reduce caesarean delivery rates in Quebec: cost-effectiveness analysis.

Johri M, Ng ESW, Bermudez-Tamayo C, Hoch JS, Ducruet T, Chaillet N.

BMC Med. 2017 May 22;15(1):96. doi: 10.1186/s12916-017-0859-8.

33.

The Clinical Significance of Occult Gastrointestinal Primary Tumours in Metastatic Cancer: A Population Retrospective Cohort Study.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan PK, Hoch JS, Zaric GS.

Cancer Res Treat. 2018 Jan;50(1):183-194. doi: 10.4143/crt.2016.532. Epub 2017 Mar 21.

34.

Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening.

Goede SL, Rabeneck L, van Ballegooijen M, Zauber AG, Paszat LF, Hoch JS, Yong JH, Kroep S, Tinmouth J, Lansdorp-Vogelaar I.

PLoS One. 2017 Mar 15;12(3):e0172864. doi: 10.1371/journal.pone.0172864. eCollection 2017.

35.

A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, Dranitsaris G, Fergusson D, Clemons M.

Support Care Cancer. 2017 Aug;25(8):2505-2513. doi: 10.1007/s00520-017-3658-z. Epub 2017 Mar 9.

PMID:
28281050
36.

Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison.

De Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD.

Healthc Policy. 2017 Feb;12(3):95-108.

37.

Hospitalization cost of conventional psychiatric care compared to broad-spectrum micronutrient treatment: literature review and case study of adult psychosis.

Kaplan BJ, Isaranuwatchai W, Hoch JS.

Int J Ment Health Syst. 2017 Jan 31;11:14. doi: 10.1186/s13033-017-0122-x. eCollection 2017.

38.

Enhancing Self-Efficacy for Help-Seeking Among Transition-Aged Youth in Postsecondary Settings With Mental Health and/or Substance Use Concerns, Using Crowd-Sourced Online and Mobile Technologies: The Thought Spot Protocol.

Wiljer D, Abi-Jaoude A, Johnson A, Ferguson G, Sanches M, Levinson A, Robb J, Heffernan O, Herzog T, Chaim G, Cleverley K, Eysenbach G, Henderson J, Hoch JS, Hollenberg E, Jiang H, Isaranuwatchai W, Law M, Sharpe S, Tripp T, Voineskos A.

JMIR Res Protoc. 2016 Nov 4;5(4):e201. doi: 10.2196/resprot.6446.

39.

Phase-specific and lifetime costs of cancer care in Ontario, Canada.

de Oliveira C, Pataky R, Bremner KE, Rangrej J, Chan KK, Cheung WY, Hoch JS, Peacock S, Krahn MD.

BMC Cancer. 2016 Oct 18;16(1):809.

40.

Advocacy for outpatient cardiac rehabilitation globally.

Babu AS, Lopez-Jimenez F, Thomas RJ, Isaranuwatchai W, Herdy AH, Hoch JS, Grace SL; in conjunction with the International Council of Cardiovascular Prevention and Rehabilitation (ICCPR).

BMC Health Serv Res. 2016 Sep 6;16:471. doi: 10.1186/s12913-016-1658-1.

41.

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.

Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, Husereau D, Pechlivanoglou P.

Clin Pharmacol. 2016 Aug 11;8:93-107. doi: 10.2147/CPAA.S105165. eCollection 2016.

42.

Potential Cost-Effectiveness of Ambulatory Cardiac Rhythm Monitoring After Cryptogenic Stroke.

Yong JH, Thavorn K, Hoch JS, Mamdani M, Thorpe KE, Dorian P, Sharma M, Laupacis A, Gladstone DJ; EMBRACE Steering Committee.

Stroke. 2016 Sep;47(9):2380-5. doi: 10.1161/STROKEAHA.115.011979. Epub 2016 Jul 28.

43.

Estimating the costs of intensity-modulated and 3-dimensional conformal radiotherapy in Ontario.

Yong JH, McGowan T, Redmond-Misner R, Beca J, Warde P, Gutierrez E, Hoch JS.

Curr Oncol. 2016 Jun;23(3):e228-38. doi: 10.3747/co.23.2998. Epub 2016 Jun 9.

44.

Potential Effects of the Choice of Costing Perspective on Cost Estimates: An Example Based on 6 Early Psychosis Intervention Programs.

Dewa CS, Trojanowski L, Cheng C, Hoch JS.

Can J Psychiatry. 2016 Aug;61(8):471-9. doi: 10.1177/0706743716639917. Epub 2016 Mar 17.

45.

Omission of Breast Radiotherapy in Low-risk Luminal A Breast Cancer: Impact on Health Care Costs.

Han K, Yap ML, Yong JH, Mittmann N, Hoch JS, Fyles AW, Warde P, Gutierrez E, Lymberiou T, Foxcroft S, Liu FF.

Clin Oncol (R Coll Radiol). 2016 Sep;28(9):587-93. doi: 10.1016/j.clon.2016.04.003. Epub 2016 Apr 29.

PMID:
27139262
46.

Walk Long and Prosper: What Is the Optimal Way to Help People Achieve Their Goals?

Hoch JS, Dewa CS.

J Gen Intern Med. 2016 Jul;31(7):712-3. doi: 10.1007/s11606-016-3709-z. No abstract available.

47.

Advice about Work-Related Issues to Peers and Employers from Head and Neck Cancer Survivors.

Dewa CS, Trojanowski L, Tamminga SJ, Ringash J, McQuestion M, Hoch JS.

PLoS One. 2016 Apr 12;11(4):e0152944. doi: 10.1371/journal.pone.0152944. eCollection 2016.

48.

Change of Outcomes in Pediatric Intestinal Failure: Use of Time-Series Analysis to Assess the Evolution of an Intestinal Rehabilitation Program.

Oliveira C, de Silva NT, Stanojevic S, Avitzur Y, Bayoumi AM, Ungar WJ, Hoch JS, Wales PW.

J Am Coll Surg. 2016 Jun;222(6):1180-1188.e3. doi: 10.1016/j.jamcollsurg.2016.03.007. Epub 2016 Mar 18.

PMID:
27067452
49.

Cost-effectiveness of using a gene expression profiling test to aid in identifying the primary tumour in patients with cancer of unknown primary.

Hannouf MB, Winquist E, Mahmud SM, Brackstone M, Sarma S, Rodrigues G, Rogan P, Hoch JS, Zaric GS.

Pharmacogenomics J. 2017 Jun;17(3):286-300. doi: 10.1038/tpj.2015.94. Epub 2016 Mar 29.

PMID:
27019982
50.

Temporal association between home nursing and hospital costs at end of life in three provinces.

Seow H, Pataky R, Lawson B, O'Leary EM, Sutradhar R, Fassbender K, McGrail K, Barbera L, Mpa MD, Burge F, Peacock SJ, Hoch JS.

Curr Oncol. 2016 Feb;23(Suppl 1):S42-51. doi: 10.3747/co.23.2971. Epub 2016 Feb 29.

Supplemental Content

Support Center